BioMark Diagnostics Inc C.BUX

Alternate Symbol(s): BMKDF

BioMark Diagnostics Inc. is a liquid biopsy company. The Company is developing a molecular diagnostics technology platform, which leverages the power of metabolomics and machine learning algorithms to bring new cancer diagnostics to market and improve cancer prognosis by allowing physicians to detect carcinomas in the pre-symptomatic stages. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. Its cancer diagnostics technology platform leverages Omics and machine learning with a focus on cancers that are hard to detect and treat cancers. Its liquid biopsy assay detects Spermidine/spermine N-acetyltransferase 1 (SSAT1). SSAT1 is an enzyme with elevated levels in numerous cancers. Its oncology has developed a new high powered liquid biopsy metabolic panel assay. The new metabolic assay is instrumental for early-stage diagnosis of lung cancer. The liquid biopsy metabolic panel has demonstrated clinical detections.

CSE:BUX - Post by User

BioMark Diagnostics Inc

<< Previous

Bullboard Posts

Next >>

Post by AlbertaCFOon Jun 15, 2021 10:58pm

219 Views

Post# 33393713

Overdue for News! Need greater USA Awareness! Promo? Any?

Need to balance the great science with business!

We need to increase awareness in USA market.

With everything that Biomark Diagnostics is doing, with US exposure, share price would already be 20X higher!

<< Previous

Bullboard Posts

Next >>

The investment impact of the U.S. 25% tariff on Canadian imports